Testing the drug M3554 in people with advanced soft tissue sarcoma or glioblastoma
Original title: Anti-GD2 ADC M3554 in Advanced Solid Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find the right dose and check for side effects.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called M3554 to find the right dose and to watch for side effects.
Who this trial is for. This trial is for adults with advanced solid tumors. The two groups named are people with soft tissue sarcoma and people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, IDH-wildtype. The trial is testing a drug called M3554. Each person takes part for about 4 months.
Where it stands. This trial has not reported results. The team is working out the doses they would recommend. They are also watching how safe the drug is and looking for early signs of an effect on tumors. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is a very early look at a new drug. It may help doctors learn the right dose and what side effects to expect. If you have soft tissue sarcoma or glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, IDH-wildtype, you could ask your care team whether a study like this fits your situation. They can explain what taking part would involve.
What it doesn't mean: This does not mean M3554 works. A trial is a test, not a proven treatment. Joining a study is not a guarantee that you will feel better or live longer. It is not a cure, and no one can promise a spot in the trial. The trial team decides who can join.
Source: ClinicalTrials.gov, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.